Search

Your search keyword '"Wang, Lin-Chun"' showing total 42 results
Start Over Author "Wang, Lin-Chun"
42 results on '"Wang, Lin-Chun"'

5. #1340 Validation of artificial intelligence algorithm classifying arteriovenous access aneurysms in hemodialysis: a blinded multicenter prospective study

Author

Dong, Zijun, primary, Zhang, Hanjie, additional, Wang, Lin-Chun, additional, Ren, Sarah, additional, Tisdale, Lela, additional, Han, Maggie, additional, Bittencourt, Valeria G, additional, Rosales Merlo, Laura, additional, Prakash-Polet, Sindhuri, additional, Douglas, Denzil, additional, Starakiewicz, Piotr, additional, Shtaynberg, Norbert, additional, Fuca, Nicholas, additional, Kozyra, Andrzej, additional, Thijssen, Stephan, additional, Preddie, Dean C, additional, and Kotanko, Peter, additional

Published
2024
Full Text
View/download PDF

8. Application of ChatGPT to Support Nutritional Recommendations for Dialysis Patients – A Qualitative and Quantitative Evaluation

Author

Wang, Lin-Chun, Zhang, Hanjie, Ginsberg, Nancy, Nandorine Ban, Andrea, Kooman, Jeroen P., and Kotanko, Peter

Abstract

The rising diversity of food preferences and the desire to provide better personalized care provide challenges to renal dietitians working in dialysis clinics. To address this situation, we explored the use of a large language model, specifically, ChatGPT using the GPT-4 model (openai.com), to support nutritional advice given to dialysis patients.

Published
2024
Full Text
View/download PDF

17. Gut Microbiome-Derived Uremic Toxin Levels in Hemodialysis Patients on Different Phosphate Binder Therapies.

Author

Wang, Lin-Chun, Tapia, Leticia M., Tao, Xia, Chao, Joshua E., Thwin, Ohnmar, Zhang, Hanjie, Thijssen, Stephan, Kotanko, Peter, and Grobe, Nadja

Subjects
*HEMODIALYSIS patients, *LIQUID chromatography-mass spectrometry, *PHOSPHATES, *TOXINS, *KIDNEY failure
Abstract

Introduction: Constipation is prevalent in patients with kidney failure partly due to the use of medication, such as phosphate binders. We hypothesized that serum levels of gut microbiome-derived uremic toxins (UTOX) may be affected by the choice of phosphate binder putatively through its impact on colonic transit time. We investigated two commonly prescribed phosphate binders, sevelamer carbonate (SEV) and sucroferric oxyhydroxide (SFO), and their association with gut microbiome-derived UTOX levels in hemodialysis (HD) patients. Methods: Weekly blood samples were collected from 16 anuric HD participants during the 5-week observational period. All participants were on active phosphate binder monotherapy with either SFO or SEV for at least 4 weeks prior to enrollment. Eight UTOX (7 gut microbiome-derived) and tryptophan were quantified using liquid chromatography-mass spectrometry. Serum phosphorus, nutritional, and liver function markers were also measured. For each substance, weekly individual levels, the median concentration per participant, and differences between SFO and SEV groups were reported. Patient-reported bowel movements, by the Bristol Stool Scale (BSS), and pill usage were assessed weekly. Results: The SEV group reported a 3.3-fold higher frequency of BSS stool types 1 and 2 (more likely constipated, p < 0.05), whereas the SFO group reported a 1.5-fold higher frequency of BSS stool types 5–7 (more likely loose stool and diarrhea, not significant). Participants in the SFO group showed a trend toward better adherence to phosphate binder therapy (SFO: 87.6% vs. SEV: 66.6%, not significant). UTOX, serum phosphorus, nutritional and liver function markers, and tryptophan were not different between the two groups. Conclusion: There was no difference in the gut microbiome-derived UTOX levels between phosphate binders (SFO vs. SEV), despite SFO therapy resulting in fewer constipated participants. This pilot study may inform study design of future clinical trials and highlights the importance of including factors beyond bowel habits and their association with UTOX levels. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

33. Retrospective analysis of the changes in the surgical treatment of benign prostatic hyperplasia during an 11-year period: a single-center experience.

Author

Peng, Zhu-Feng, Zhou, Jing, Song, Pan, Yang, Lu-Chen, Yang, Bo, Ren, Zheng-Ju, Wang, Lin-Chun, Wei, Qiang, and Dong, Qiang

Abstract

The present study aimed to determine whether the number of patients with symptomatic benign prostatic hyperplasia (BPH) who preferred surgery decreased during the past 11 years at our center (West China Hospital, Chengdu, China), and whether this change affected the timing of surgery and the physical condition of surgical patients. This retrospective study included 57 557 patients with BPH treated from January 2008 to December 2018. Of these, 5427 patients were treated surgically. Surgical patients were divided into two groups based on the time of treatment (groups 8–13 and groups 13–18). The collected data comprised the percentage of all patients with BPH who underwent surgery, baseline characteristics of surgical patients, rehabilitation time, adverse events, and hospitalization costs. The surgery rates in groups 8–13 and groups 13–18 were 10.5% and 8.5% (P < 0.001), respectively. The two groups did not clinically differ regarding patient age and prostate volume. The rates of acute urinary retention and renal failure decreased from 15.0% to 10.6% (P < 0.001) and from 5.2% to 3.1% (P < 0.001), respectively. In groups 8–13 and groups 13–18, the mean catheterization times were 4.0 ± 1.7 days and 3.3 ± 1.6 days (P < 0.001), respectively, and the mean postoperative hospitalization times were 5.1 ± 2.4 days and 4.2 ± 1.8 days (P < 0.001), respectively. The incidences of unplanned second surgery and death reduced during the study period. The surgery rate decreased over time, which suggests that medication was chosen over surgery. However, the percentage of late complications of BPH also decreased over time, which indicates that the timing of surgery was not delayed. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

42. Enhanced recovery after surgery in transurethral surgery for benign prostatic hyperplasia.

Author

Zhou J, Peng ZF, Song P, Yang LC, Liu ZH, Shi SK, Wang LC, Chen JH, Liu LR, and Dong Q

Subjects
Male, Humans, Quality of Life, Treatment Outcome, Prostatic Hyperplasia complications, Transurethral Resection of Prostate adverse effects, Enhanced Recovery After Surgery
Abstract

Enhanced recovery after surgery (ERAS) measures have not been systematically applied in transurethral surgery for benign prostatic hyperplasia (BPH). This study was performed on patients with BPH who required surgical intervention. From July 2019 to June 2020, the ERAS program was applied to 248 patients, and the conventional program was applied to 238 patients. After 1 year of follow-up, the differences between the ERAS group and the conventional group were evaluated. The ERAS group had a shorter time of urinary catheterization compared with the conventional group (mean ± standard deviation [s.d.]: 1.0 ± 0.4 days vs 2.7 ± 0.8 days, P < 0.01), and the pain (mean ± s.d.) was significantly reduced through postoperative hospitalization days (PODs) 0-2 (POD 0: 1.7 ± 0.8 vs 2.4 ± 1.0, P < 0.01; POD 1: 1.6 ± 0.9 vs 3.5 ± 1.3, P < 0.01; POD 2: 1.2 ± 0.7 vs 3.0 ± 1.3, P < 0.01). No statistically significant difference was found in the rate of postoperative complications, such as postoperative bleeding (P = 0.79), urinary retention (P = 0.40), fever (P = 0.55), and readmission (P = 0.71). The hospitalization cost of the ERAS group was similar to that of the conventional group (mean ± s.d.: 16 927.8 ± 5808.1 Chinese Yuan [CNY] vs 17 044.1 ± 5830.7 CNY, P =0.85). The International Prostate Symptom Scores (IPSS) and quality of life (QoL) scores in the two groups were also similar when compared at 1 month, 3 months, 6 months, and 12 months after discharge. The ERAS program we conducted was safe, repeatable, and efficient. In conclusion, patients undergoing the ERAS program experienced less postoperative stress than those undergoing the conventional program., Competing Interests: None

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results